Stay updated with breaking news from Cornea Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved ...
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, told investors it has filed an Investigational New Drug (IND) application with the US Food...
A team led by researchers from Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.
The results of early-stage research into a procedure developed to treat limbal stem cell deficiency have been published. The disease is a corneal disorder that can occur after chemical burns and other eye injuries. A larger study is underway.
FRIDAY, Aug. 18, 2023 (HealthDay News) -- Phillip Durst was working near an industrial dishwasher when something went awry, and the machinery spewed caustic chemicals into his eyes.